| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7598343 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
| US7582727 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
|
US7582727 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(5 years from now) | |
|
US7598343 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(5 years from now) | |
Angiomax is owned by Sandoz Inc.
Angiomax contains Bivalirudin.
Angiomax has a total of 4 drug patents out of which 0 drug patents have expired.
Angiomax was authorised for market use on 15 December, 2000.
Angiomax is available in injectable;intravenous dosage forms.
The generics of Angiomax are possible to be released after 27 January, 2029.
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage
ANGIOMAX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic